Answers are grounded in this paper and cite their sources.
Adenovirus vectors are a major vaccine platform and have potential roles as oncolytics and gene therapies. Large‐scale production of adenovirus‐vectored COVID‐19 vaccines demonstrated the value of platform manufacturing processes for such products but vaccine scarcity remained problematic in 2021. There is a need for widely‐accessible and higher‐yielding platform processes for adenovirus production. Such processes must overcome cell‐density‐associated productivity limitation and the potential impact of vector transgene expression. We report a process capable of upstream productivity of 3 ×10 12 virus particles per mL, solely using commercially‐accessible materials. This combines perfusion cell culture with a highly‐productive cell line capable of vector transgene repression. Using a multi‐parallel scaledown perfusion bioreactor system, we selected straightforward perfusion conditions for both expansion of uninfected cells and virus production. This achieves maintenance of high cell‐specific productivity at cell densities up to 40 ×10 6 cells per mL. We believe this may be the highest productivity yet reported for an adenovirus platform, including previous reports using proprietary cell lines. This highly productive process could be valuable both in large‐scale production and in maximizing the output of smaller facilities making products for niche indications or stockpiles.
No takes yet. Share an insight, caveat, or question.
Rosskamp et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: